MMS Holdings has acquired Exploristics, enhancing its data-driven clinical research capabilities and expanding its global presence in the biotechnology and pharmaceutical sectors.

Target Company Overview

MMS Holdings, headquartered in Canton, Michigan, is an award-winning, data-driven clinical research organization (CRO) known for its expertise in offering advanced solutions in drug development and regulatory submissions. The company specializes in enhancing clinical trial efficacy through innovative statistical design and data science techniques. With a strong history of organic growth, MMS is widely recognized for its commitment to improving trial outcomes for biotechnology and pharmaceutical sponsors.

The recent acquisition of Exploristics, a prominent biostatistics and data science company located in Belfast, Northern Ireland, is set to expand MMS’s capabilities significantly. By integrating Exploristics’ flagship product, KerusCloud®, a state-of-the-art cloud-based statistical modeling platform, MMS aims to further its mission of optimizing drug development processes and delivering higher quality results for clients.

Industry Overview in the United Kingdom

The clinical research sector in the United Kingdom is experiencing robust growth driven by advancements in biostatistical methods and increasing investments in life sciences. The UK has established itself as a global h